Literature DB >> 30318320

Which grade is of clinical benefit in the randomised controlled trials? The example of 54th American Society of Clinical Oncology annual meeting, 2018.

Jacopo Giuliani1, Andrea Bonetti2.   

Abstract

Keywords:  ASCO Annual Meeting; Breast cancer; Colorectal cancer; NSCLC

Mesh：

Year:  2018        PMID： 30318320     DOI： 10.1016/j.ejca.2018.08.026

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  1 in total

1.  Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer.

Authors:  Jacopo Giuliani; Andrea Bonetti
Journal:  Cancer Drug Resist       Date:  2021-04-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.